about
Entecavir for chronic hepatitis BEntecavir for chronic hepatitis BA Canadian national survey of attitudes and knowledge regarding preventive vaccinesSystematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.Direct-Acting Antiviral Agents for Chronic Hepatitis C Genotype 1Drugs for Chronic Hepatitis C Infection: Cost-Effectiveness AnalysisEconomic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysisModelling mitigation strategies for pandemic (H1N1) 2009.Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.Lack of comprehension of common prostate cancer terms in an underserved population.Specialized multi-disciplinary heart failure clinics in Ontario, Canada: an environmental scanConceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.Using Phase-Based Costing of Real-World Data to Inform Decision-Analytic Models for Atrial Fibrillation.Incremental health care costs for chronic pain in Ontario, Canada: a population-based matched cohort study of adolescents and adults using administrative data.Health utilities in people with chronic pain using a population-level survey and linked health care administrative data.Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A.A review of interventions triggered by hepatitis A infected food-handlers in CanadaInitial bone marrow aspiration in childhood idiopathic thrombocytopenia: decision analysis.Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P)Health status utilities and the impact of pressure ulcers in long-term care residents in OntarioFeasibility of internet-based health-related quality of life data collection in a large patient cohort.Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Principles of economic evaluation in surgery.Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the LiteratureNeck pain patients' preference scores for their current health.Pressure ulcer multidisciplinary teams via telemedicine: a pragmatic cluster randomized stepped wedge trial in long term care.Early economic evaluation of emerging health technologies: protocol of a systematic review.Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.Techniques for estimating health care costs with censored data: an overview for the health services researcherInfluence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009.How much are we spending? The estimation of research expenditures on cardiovascular disease in CanadaHealth care costs associated with hepatitis C: a longitudinal cohort studyUnderstanding the role of scientific evidence in consumer evaluation of natural health products for osteoarthritis an application of the means end chain approachTenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
P50
Q24195119-B882BBA0-5E69-45A2-A914-287312573F45Q24244842-C3695C8A-C485-4A7D-8260-463E41A99752Q24798043-DF50C142-32E7-4419-AE48-691FB3154FB8Q27337981-BA8BB2E7-93BE-4F45-B37C-BADE4C2A7EFEQ28067410-3368C88F-32F7-4CD0-B48A-B5C56921E89EQ28078782-6CC5EEFC-AD82-43CA-AEE3-C562F3E8FEBFQ28748161-945AD1C1-2EDA-4E19-A258-0FBCD416F6E6Q30381617-D3281A52-7EC1-4E16-BCA1-0AEFAA841F26Q30384008-5269713C-37CD-4962-9304-F5D1D90E40E3Q30391605-E867485D-B60D-4028-9750-07168FF3A113Q30436410-3CB76C60-8A4B-4B5F-AE4B-33146738B331Q30528623-ABAE0CC9-CFD4-4F13-98BF-615EF6E5855DQ30595581-FD5C2456-2BFD-4982-947E-62109EFC7B38Q30613075-65AECB1F-0623-49FD-84B7-26EB8AE8D892Q30991092-B3BD5527-205D-4218-B087-C36A504E716EQ31049878-D9EAE2B7-C1E1-4A5E-83C3-0D75A8D77773Q31060343-FC88A0C5-0FA3-425B-8B52-F3031AD912B8Q31146137-4DC01E3C-96C3-4799-A83A-2AD72C19B199Q33265523-1CC38B26-5B25-499B-B965-779B007D266AQ33265950-3C88FDD0-7183-43A6-9923-91013EDFAF60Q33341329-5B642487-3A49-4D95-A186-377BFA617C7CQ33418504-328B7D91-5F0E-41AA-907D-30C7D19DF7EFQ33443421-59325B4D-84A4-411C-BC8A-93C16005831BQ33495763-057AF860-D948-4690-949B-A24F2250FEFDQ33583559-2DA68D80-C671-44C0-AEED-136FCEB54ADAQ33663119-3D0FBF0C-E460-4CC0-B939-AA96696E50ECQ33763924-5E0A6841-69C0-4CD6-9533-09165815A964Q33769216-2506ED73-3167-47B6-98C7-95C80CC7E74FQ33836709-5F48BA17-355F-46DA-BE61-69BD102C70CFQ33845622-7B11C521-416B-41D9-9658-EFEFD4F1F659Q33866813-BBD1D820-B80F-4AEE-93C2-E107A112CA73Q33923557-9C73D140-82C9-44C7-A68C-1DFC91064D96Q33968510-0958902F-23C2-4BB8-8AA8-5218ACE566C7Q34105982-BFF1662A-4256-4E13-9793-073E3029ABFDQ34311479-7DAA6853-DF66-446C-9CC3-FD20DEB0CB86Q34342497-6595474C-E640-4CDB-938D-CF81F24C6826Q34396562-64A1FF8F-B452-4A35-9226-8C4B4A528E3AQ34417139-96274CE4-05EB-41DB-AF08-C43ED65A9BBFQ34459717-0057215A-C89B-4FD7-99A5-9355F9F14741Q34621209-584580C5-A567-4AC9-A370-809DB0E0A61A
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Murray Krahn
@ast
Murray Krahn
@en
Murray Krahn
@es
Murray Krahn
@nl
Murray Krahn
@sl
type
label
Murray Krahn
@ast
Murray Krahn
@en
Murray Krahn
@es
Murray Krahn
@nl
Murray Krahn
@sl
prefLabel
Murray Krahn
@ast
Murray Krahn
@en
Murray Krahn
@es
Murray Krahn
@nl
Murray Krahn
@sl
P214
P244
P106
P1153
7005004050
P21
P214
P244
n2002152173
P31
P3835
murray-krahn
P496
0000-0001-5836-397X
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-n2002152173